

# CITRINE GLOBAL, CORP.

## **FORM 8-K** (Current report filing)

Filed 09/29/23 for the Period Ending 09/28/23

Telephone	972-73-7600341
CIK	0001498067
Symbol	CTGL
SIC Code	7372 - Services-Prepackaged Software
Industry	Medical Equipment, Supplies & Distribution
Sector	Healthcare
Fiscal Year	12/31

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): **September 28, 2023**

**CITRINE GLOBAL, CORP.**

**Delaware**  
(State or Other Jurisdiction  
Of incorporation)

**000-55680**  
(Commission  
File Number)

**68-0080601**  
(IRS Employer  
Identification Number)

**5 Golden Beach, Caesarea, Israel**  
(Address of Principal Executive Offices)

**3088900**  
(Zip code)

**+ (972) 9 855 1422**  
(Registrant's telephone number, including area code)

**Not applicable**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
N/A	N/A	N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

---

**Item 1.01 Entry into a Material Definitive Agreement.**

On September 28, 2023, Citrine Global, Corp. (the “Company”) and MyPlant Bio Ltd. (“MyPlant”) entered into an amendment of the Share Purchase and Option Agreement to which they are parties (the “Share Purchase and Option Agreement”) to extend to December 31, 2023 the option exercise period available to the Company to purchase an additional 45% of MyPlant’s share equity, on a fully diluted basis. All other terms and conditions of the Share Purchase and Option Agreement remain in full force and effect.

The Share Purchase and Option Agreement, the material terms of which were disclosed in the Company’s current report on Form 8-K filed on January 6, 2023, includes the grant of an option to the Company, exercisable in the Company’s sole discretion, from MyPlant and the MyPlant shareholders to purchase the additional share capital.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

**CITRINE GLOBAL, CORP.**

Date: September 29, 2023

By: /s/ Ora Elharar Soffer

Name: Ora Elharar Soffer

Title: Chief Executive Officer (principal executive officer)

---